CLYM

9.1801.08%
AM

Aoife M. Brennan

CEO, President & Director

Dr. Aoife M. Brennan, M.D. M.B., Ch.B., BAO, MMSc, MRCPI, is CEO, President at Climb Bio, Inc. (formerly known as Eliem Therapeutics, Inc.) and serves as its Director since June 2024 and served as its Interim Principal Financial Officer since May 24, 2025. Dr. Brennan serves as Independent Director of Xilio Therapeutics, Inc. since June 2024. Dr. Brennan served as Director at FibroGen, Inc. since August 5, 2020 until June 2025. Dr. Brennan was Advisor of Atlas Venture L.P. until 2025. Dr. Brennan was employed at Atlas Venture L.P. until 2025. Dr. Brennan serves as Director at Cerevance LLC. from January 1, 2020. She served as Director at Ra Pharmaceuticals, Inc since September 21, 2018 through its acquisition in April 2020. Dr. Brennan was the President, Chief Executive Officer and Director of Synlogic Inc. since October 2, 2018 until February 2024. She served as Chief Medical Officer of Synlogic, Inc. since September 12, 2016 until September 4, 2019 and had served as its Interim President & CEO from May 2018 to October 2, 2018. Dr. Brennan is responsible for the oversight and direction of the Synlogic's clinical development strategy and operations. Dr. Brennan joined Synlogic following at Biogen, where she was in roles of increasing responsibility and served as vice president and head of the Rare Disease Innovation Unit, which included programs ranging from pre-clinical to commercial. She has also led programs across multiple therapeutic areas including the late phase development of nusinersen for spinal muscular atrophy and ALPROLIX and ELOCTATE, treatments for Hemophilia B and Hemophilia A. Prior to joining Synlogic, Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen where her responsibilities included the global marketing approvals of ALPROLIX, ELOCTATE and SPINRAZA as well as the advancement of several early-phase programs and external collaborations. She served as Senior Medical Director of Clinical Development at Biogen Inc. (alternate name, Biogen Idec Inc.). Prior to joining Biogen, Dr. Brennan was Director of Clinical Development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 diabetes. She is a member of the advisory board of the Harvard Masters in Clinical Investigation Program. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program. She completed residency and fellowship training in general internal medicine and endocrinology. Dr. Brennan holds a medical degree from Trinity College Dublin, Ireland and has completed post-graduate training in internal medicine, endocrinology and metabolism. Prior to joining the biotechnology industry, she was a Clinical Research Fellow in the Division of Endocrinology, Diabetes and Metabolism at Beth Israel Deaconess Medical Center and the Joslin Diabetes Center in Boston.

Positions